Qiagen lowers 2026 forecast due to reduced demand for immigration tests and cautious US Life Sciences spending

se.investing.com (Swedish)

Qiagen lowered its 2026 forecast due to decreased demand for immigration testing and cautious spending by US Life Sciences customers. The company reported preliminary Q1 2026 net sales of $492 million, a 2% increase year-over-year, missing its growth forecast. Adjusted diluted EPS met expectations at $0.54. Qiagen now anticipates 1-2% full-year net sales growth, down from its previous 5% projection, citing a 5% drop in QuantiFERON sales.


With a significance score of 1, this news ranks in the top 68% of today's 32668 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Qiagen lowers 2026 forecast due to reduced demand for immigration tests and cautious US Life Sciences spending | News Minimalist